Sandor Rado, American psychoanalysis, and the question of bisexuality.

The Hungarian-born physician and psychoanalyst Sandor Rado (1890-1972), who practiced for most of his career in the United States, played a central role in shaping American psychoanalysts' views toward homosexuality. Historians have pointed to Rado's rejection of Freud's notion of constitutional bisexuality as the key theoretical maneuver that both pathologized homosexuality and inspired an optimistic approach to its treatment. Yet scholarly analysis of the arguments that Rado made for his rejection of bisexuality is lacking. This article seeks to provide that analysis, by carefully reviewing and evaluating Rado's arguments by the standards of his own day. Because one of Rado's main arguments is that bisexuality is an outdated concept according to modern biology, I consider what contemporary biologists had to say on the topic. The work of behavioral endocrinologist Frank Beach (1911-1988) is important in this context and receives significant attention here. Rado ultimately distanced himself from Beach's behavioral endocrinology, appealing instead to evolutionary discourse to buttress his claim that homosexuality is pathological. This tactic allowed him to refashion psychoanalysis into a moralistic discipline, one with closer ties to a medical school. (PsycINFO Database Record

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

With the recent FDA approvals of pembrolizumab and nivolumab, and a host of additional immunomodulatory agents entering clinical development each year, the field of cancer immunotherapy is changing rapidly. Strategies that can assist researchers in choosing the most promising drugs and drug combinations to move forward through clinical development are badly needed in order to reduce the likelihood of late-stage clinical trial failures. On October 5, 2014, the Cancer Immunotherapy Consortium of the Cancer Research Institute, a collaborative think tank composed of stakeholders from academia, industry, regulatory agencies, and patient interest groups, met to discuss strategies for de-risking immunotherapy development, with a focus on integrating preclinical and clinical studies, and conducting smarter early-phase trials, particularly for combination therapies. Several recommendations were made, including making better use of clinical data to inform preclinical research, obtaining adequate tissues for biomarker studies, and choosing appropriate clinical trial endpoints to identify promising drug candidates and combinations in nonrandomized early-phase trials.

Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference.

The inaugural International Cancer Immunotherapy Conference, cohosted by the Cancer Research Institute (CRI), the American Association for Cancer Research (AACR), the Association for Cancer Immunotherapy (CIMT), and the European Academy of Tumor Immunology (EATI), was held in New York City on September 16­19, 2015. The conference brought together nearly 1,400 scientists, clinicians, regulators, patient advocates, and other stakeholders to discuss the latest scientific developments in cancer immunology and immunotherapy, as well as the regulatory hurdles facing new drug development. This conference report summarizes the main themes that emerged during the 4-day meeting.

Cancer immunotherapy out of the gate: the 22nd annual Cancer Research Institute International Immunotherapy Symposium.

The 22nd annual Cancer Research Institute (CRI) International Immunotherapy Symposium was held from October 5-8, 2014, in New York City. Titled "Cancer Immunotherapy: Out of the Gate," the symposium began with a Cancer Immunotherapy Consortium satellite meeting focused on issues in immunotherapy drug development, followed by five speaker sessions and a poster session devoted to basic and clinical cancer immunology research. The second annual William B. Coley lecture was delivered by Lieping Chen, one of the four recipients of the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology; the other three recipients were Gordon Freeman, Tasuku Honjo, and Arlene Sharpe. Prominent themes of the conference were the use of genomic technologies to identify neoantigens and the emergence of new immune modulatory molecules, beyond CTLA-4 and PD-1/PD-L1, as new therapeutic targets for immunotherapy.

The Cancer Research Institute 2013 Annual Symposium: Dynamics of host-tumor interaction.

The 21st annual Cancer Research Institute (CRI) cancer immunotherapy symposium, entitled "Dynamics of Host-Tumor Interaction," was held in New York City from September 30 through October 2, 2013. The symposium comprised 27 presentations, organized into five sessions and exploring such topics as the role of chronic inflammation in creating a protumorigenic microenvironment, the interactions between the cancer stroma and immune cells in trafficking and cancer metastasis, the role of the host microbiota in immune responses to cancer, and the interactions between cancer cells and immunoregulatory elements, including regulatory T cells and T-cell checkpoint proteins. The conference began with a keynote address by Michael Karin, recipient of the 2013 Coley Award, who discussed the role of inflammation as a Janus-faced process in the body's fight against cancer-both tumor destroying and tumor promoting. The conference concluded with a session on therapeutics and translational research aimed at improving existing cancer immunotherapies.